# Fasting Study of Albuterol Sulfate Extended-Release Tablets 8 mg and VoSpire® ER Tablets 8 mg

> **NCT00649779** · PHASE1 · COMPLETED · sponsor: **Mylan Pharmaceuticals Inc** · enrollment: 21 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** albuterol sulfate extended-release 8 mg tablets
- **DRUG:** VoSpire™ ER 8 mg tablets

## Key facts

- **NCT ID:** NCT00649779
- **Lead sponsor:** Mylan Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2005-10
- **Final completion:** 2005-10
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2008-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00649779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00649779, "Fasting Study of Albuterol Sulfate Extended-Release Tablets 8 mg and VoSpire® ER Tablets 8 mg". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00649779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*